Petrelintide

DB19442InvestigationalProtein Based Therapies

Petrelintide is under investigation in clinical trial NCT06662539 (Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities).

Mechanism: Pharmacologically active on Calcitonin receptor
Curator reviewed
Also known as: 3,8-anhydro[N-(19-carboxynonadecanoyl)- L-γ-glutamyl-L-arginyl-L-α-aspartylglycyl-L-threonyl-L-alanyl-L-threonyl-L -lysyl-L-alanyl-L-threonyl-L-α-glutamyl-L-arginyl-L-leucyl-L-alanyl-(2S)-α-2-aminoadipyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-arginyl · L-Prolinamide, N-(19-carboxy-1-oxononadecyl)-L-γ-glutamyl-L-arginyl-L-α-aspartylglycyl-L-threonyl-L-alanyl-L-threonyl-L-lysyl-L-alanyl-L-threonyl-L-α-glutamyl-L-arginyl-L-leucyl-L-alanyl-5-carboxy-L-norvalyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-argi

Resolves to

Compound

UNIID78KBY7BRUCAS2766385-23-1

Targets

P30988CALCR

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Petrelintide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account